Human CD141⁺ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model

Abstract

These data illustrate quantitative and qualitative impairments in circulating CD141⁺ DCs in patients with advanced melanoma and that increasing CD141⁺ DC number and function is an attractive strategy to enhance immunogenicity and response rates to ICIs.